Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Neuro-Cells in Chronic Traumatic Spinal Cord Injury
NCT04205019Phase 1Completed
- Sponsor
- Neuroplast
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Neuro-Cells in traumatic spinal cord injury (TSCI), sponsored by Neuroplast. Primary endpoints: Safety of intrathecal administration of Neuro-Cells by ISNCSCI checklist at 3 months, Safety of intrathecal administration of Neuro-Cells assessed by blood at 3 months and 2 more. Started Nov 2020; status: completed.
02
Drugs
Neuro-Cells
03
Conditions
traumatic spinal cord injury (TSCI)
Beyond the preview
Go deeper on NCT04205019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205019.